[Treatment of arthritic psoriasis with Demoplas Clinical and scintigraphic study in 10 patients (author's transl)].
Clinical, X-ray, and scintigraphic (6mCi 99mtechnetium pertechnetate, 4mCi 99mtechnetium pyrophosphate) tests for joint involvement were conducted on 11 inpatients with psoriasis (4 female, 7 male), 6 of them cases of what is conventionally termed psoriatic arthropathy. These tests were performed both before and after a 12-day period of therapy with daily 4 x 1 coated tablets of Demoplas containing 150 mg phenylbutazone Scintigraphic tests showed that pathological radionuclide concentrations were present in at least one joint or group of joints in 10 out of 11 patients. Following therapy the previously pathological scintigraphic findings had stabilized completely in 4 patients and partially in 3 patients, but had not stabilized in 3 patients. The results of therapy with Demoplas as demonstrated by joint scintigraphy were thus good to satisfactory in 7 patients and unsatisfactory in 3 patients- possibly owing to the short duration of therapy. The improvement in scintigraphic results testifies to the therapeutic action of phenylbutazone on arthritic psoriasis. This can also be regarded as additional proof that psoriatic joint involvement is of an inflammatory and proliferative nature.
D000328:Adult; D000368:Aged; D001168:Arthritis / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007592:Joint Diseases / Q000175:diagnosis; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000627:therapeutic use*; D011565:Psoriasis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D011877:Radionuclide Imaging; D013667:Technetium
D013667:Technetium; D010653:Phenylbutazone
Zur Therapie der Arthritis psoriatica mit Demoplas